NASDAQ:MNOV MediciNova (MNOV) Stock Price, News & Analysis $1.82 -0.16 (-8.08%) (As of 09/13/2024 ET) Add Compare Share Share Today's Range$1.68▼$2.0150-Day Range$1.13▼$2.1052-Week Range$1.12▼$2.38Volume41,152 shsAverage Volume42,100 shsMarket Capitalization$89.27 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get MediciNova alerts: Email Address MediciNova MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestBearish0.40% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.22Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.24) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.04 out of 5 starsMedical Sector917th out of 922 stocksPharmaceutical Preparations Industry427th out of 429 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for MediciNova.Read more about MediciNova's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted0.40% of the float of MediciNova has been sold short.Short Interest Ratio / Days to CoverMediciNova has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in MediciNova has recently increased by 104.34%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMediciNova does not currently pay a dividend.Dividend GrowthMediciNova does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MNOV. Previous Next 2.3 News and Social Media Coverage News SentimentMediciNova has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for MediciNova this week, compared to 1 article on an average week.MarketBeat Follows3 people have added MediciNova to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, MediciNova insiders have not sold or bought any company stock.Percentage Held by Insiders14.90% of the stock of MediciNova is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 9.90% of the stock of MediciNova is held by institutions.Read more about MediciNova's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for MediciNova are expected to decrease in the coming year, from ($0.23) to ($0.24) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of MediciNova is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of MediciNova is -10.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMediciNova has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about MediciNova's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Click here for the ticker >>> About MediciNova Stock (NASDAQ:MNOV)MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. The company's product pipeline also includes MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the treatment of acute exacerbations of asthma; MN-001 (tipelukast), an orally bioavailable small molecule compound to treat fibrotic and other diseases, including nonalcoholic fatty liver disease and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent for treating solid tumor cancers. It has license agreements with Kyorin Pharmaceutical Co., Ltd; Angiogene Pharmaceuticals, Ltd.; and Meiji Seika Kaisha, Ltd. The company was incorporated in 2000 and is headquartered in La Jolla, California.Read More MNOV Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MNOV Stock News HeadlinesSeptember 14 at 1:29 AM | americanbankingnews.comStockNews.com Initiates Coverage on MediciNova (NASDAQ:MNOV)September 9, 2024 | globenewswire.comMediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MNDSeptember 14, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year. September 5, 2024 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Now Covered by StockNews.comSeptember 4, 2024 | americanbankingnews.comMediciNova (NASDAQ:MNOV) Stock Price Crosses Above 200 Day Moving Average of $1.36September 3, 2024 | globenewswire.comMediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) MeetingAugust 29, 2024 | globenewswire.comMediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID ConditionAugust 28, 2024 | finance.yahoo.comMediciNova (NASDAQ:MNOV) Is In A Good Position To Deliver On Growth PlansSeptember 14, 2024 | Porter & Company (Ad)War on Elon Escalates… Elon Musk just built a supercomputer in Memphis, Tennessee. It took him only 122 days. Dubbed “Colossus,” this supercomputer aims to become the most powerful AI training system in the world. Housed in a 785,000 sq. ft facility in Memphis, Colossus will soon require 150 megawatts of electricity per day. That’s about equal to the amount of energy needed to power 100,000 homes per year. August 20, 2024 | finance.yahoo.comMNOV Sep 2024 2.500 call (MNOV240920C00002500)July 26, 2024 | finance.yahoo.comMediciNova, Inc. (MNOV)June 20, 2024 | globenewswire.comMediciNova Chief Business Officer David H. Crean, Ph.D.June 5, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid CancerJune 3, 2024 | globenewswire.comMediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024May 28, 2024 | globenewswire.comMediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic ConditionsMay 20, 2024 | stockhouse.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 20, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye CancerMay 14, 2024 | globenewswire.comMediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress SyndromeSee More Headlines Receive MNOV Stock News and Ratings via Email Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/08/2024Today9/13/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MNOV CUSIPN/A CIK1226616 Webmedicinova.com Phone(858) 373-1500Fax858-404-0048Employees10Year Founded2000Profitability EPS (Most Recent Fiscal Year)($0.17) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-8,560,000.00 Net MarginsN/A Pretax Margin-816.10% Return on Equity-13.37% Return on Assets-12.67% Debt Debt-to-Equity RatioN/A Current Ratio18.25 Quick Ratio18.25 Sales & Book Value Annual Sales$1 million Price / Sales89.27 Cash FlowN/A Price / Cash FlowN/A Book Value$1.27 per share Price / Book1.43Miscellaneous Outstanding Shares49,050,000Free Float41,738,000Market Cap$89.27 million OptionableOptionable Beta0.72 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Yuichi Iwaki M.D. (Age 74)Ph.D., Co-Founder, President, CEO & Executive Director Comp: $933.05kDr. Kazuko Matsuda M.D. (Age 58)M.P.H., Ph.D., Chief Medical Officer & Director Comp: $653.65kMr. Jason J. Kruger CPA (Age 46)CFO & Principal Financial Officer Dr. David H. Crean M.B.A. (Age 59)Ph.D., Chief Business Officer Mr. John O'Neil CPAControllerKey CompetitorsVerrica PharmaceuticalsNASDAQ:VRCAVerastemNASDAQ:VSTMHookipa PharmaNASDAQ:HOOKKezar Life SciencesNASDAQ:KZRNextCureNASDAQ:NXTCView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 20,400 shares on 8/9/2024Ownership: 0.428%Dimensional Fund Advisors LPSold 38,322 shares on 8/9/2024Ownership: 0.141%View All Institutional Transactions MNOV Stock Analysis - Frequently Asked Questions How have MNOV shares performed this year? MediciNova's stock was trading at $1.50 at the start of the year. Since then, MNOV stock has increased by 21.3% and is now trading at $1.82. View the best growth stocks for 2024 here. How were MediciNova's earnings last quarter? MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.06) by $0.01. Who are MediciNova's major shareholders? Top institutional shareholders of MediciNova include Renaissance Technologies LLC (0.43%) and Dimensional Fund Advisors LP (0.14%). View institutional ownership trends. How do I buy shares of MediciNova? Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of MediciNova own? Based on aggregate information from My MarketBeat watchlists, some other companies that MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). This page (NASDAQ:MNOV) was last updated on 9/14/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored44-year Wall Street Vet: “Permanent devastation is coming to America”After 44 years on Wall Street, I've seen it all... Black Monday, the Great Recession, the Covid crash. B...InvestorPlace | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredInvest before this deal closes on 9/18This company can create aviation fuels from waste, they qualify to help airlines meet net-zero carbon pledges ...Deal Maker | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MediciNova, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MediciNova With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
